Condition: Depression · Depressive Disorder · Overweight or Obesity · Sponsor: Riphah International University
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
This description comes directly from the study's public registry record.
Afifa Siddique, PhD Scholar, MBBS, M.Phil · +923175441910 · dr.afifa.siddique@gmail.com
Tayaba Farooq, MBBS, M.Phil · +92 333 5244374 · drafifa.one@gmail.com
Always discuss trial participation with your own doctor first.
| Pakistan Railway Hospital | Rawalpindi, Punjab Province, Pakistan | Recruiting |
| Afifa Siddique | Rawalpindi, Punjab Province, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07654179